Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)
Alba Cabirta,Pau Abrisqueta,Víctor Navarro Garcés, Marta Canelo-Vilaseca, Marina Gomez-Rosa,Alberto Lopez García,Tomas García,Fatima De la Cruz,Juan-Manuel Sancho,Eduardo Rios Herranz,Raul Cordoba,Angel Serna,Moraima Jiménez,Sabela Bobillo,Marta Julia,Cecilia Carpio,Gloria Iacoboni,Laura Gallur,Josep Castellvi,Francesc Bosch Blood（2022）
AI 理解论文
溯源树
样例
